Octanoic Acid

Octanoic Acid

SCHEMBL1661278

CCCCCCCC(=O)[O-].CC[n+]1ccn(C)c1

nearest known ligand 0.51

Full drug profile on Sugi Atlas →

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
FABP3 P05413 7/20 0.45
MEN1 O00255 1/20 0.43
HSP90AA1 P07900 1/20 0.43
KMT2A Q03164 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CA1 P00915 1/20 0.42
FDPS P14324 6/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Decanoic Acid SCHEMBL1662199 1.00 FABP3 (0.45) FABP3MEN1HSP90AA1KMT2ASMN1; SMN2
Dodecanoate SCHEMBL1661287 1.00 FABP3 (0.45) FABP3MEN1HSP90AA1KMT2ASMN1; SMN2
Heptanoate SCHEMBL1661522 1.00 FABP3 (0.45) FABP3MEN1HSP90AA1KMT2ASMN1; SMN2
Stearic Acid SCHEMBL22362218 1.00 FABP3 (0.45) FABP3MEN1HSP90AA1KMT2ASMN1; SMN2
Nonanoate SCHEMBL1661376 1.00 FABP3 (0.45) FABP3MEN1HSP90AA1KMT2ASMN1; SMN2
Undecanoate SCHEMBL1663984 1.00 FABP3 (0.45) FABP3MEN1HSP90AA1KMT2ASMN1; SMN2
Palmitic Acid SCHEMBL28783479 0.90 FABP3 (0.44) FABP3MEN1HSP90AA1KMT2ASMN1; SMN2
Palmitic Acid SCHEMBL28783469 0.90 FABP3 (0.44) FABP3MEN1HSP90AA1KMT2ASMN1; SMN2
Palmitic Acid SCHEMBL28783450 0.90 FABP3 (0.44) FABP3MEN1HSP90AA1KMT2ASMN1; SMN2
Myristic Acid SCHEMBL28783468 0.90 FABP3 (0.44) FABP3MEN1HSP90AA1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190024263-A1 LYOCELL FIBER AND MANUFACTURING METHOD THEREFOR KOLON INDUSTRIES, INC. (KR) 2019-01-24 US claimed
EP-2486175-B1 A PROCESS OF MANUFACTURING LOW FIBRILLATING CELLULOSE FIBERS GRASIM IND LTD (IN) 2015-05-20 EP claimed
US-8952146-B2 Process for manufacturing low-fibrillating cellulosic fiber GRASIM INDUSTRIES LIMITED (IN) 2015-02-10 US claimed
WO-2014207100-A1 A PROCESS FOR COATING PAPER WITH CELLULOSE USING A SOLUTION CONTAINING CELLULOSE BASF SE (DE) 2014-12-31 WO claimed
US-8841441-B2 Method for producing regenerated biopolymers and regenerated products obtained by said method BASF SE (DE) 2014-09-23 US claimed
EP-1966284-B1 SOLVENT SYSTEM BASED ON MOLTEN IONIC LIQUIDS, ITS PRODUCTION AND USE FOR PRODUCING REGENERATED CARBOHYDRATES BASF SE (DE) 2013-04-17 EP claimed
US-20120253030-A1 PROCESS FOR MANUFACTURING LOW-FIBRILLATING CELLULOSIC FIBER GRASIM INDUSTRIES LIMITED (IN) 2012-10-04 US claimed
US-20120253031-A1 PROCESS FOR MANUFACTURING LOW-FIBRILLATING CELLULOSIC FIBER GRASIM INDUSTRIES LIMITED (IN) 2012-10-04 US claimed
EP-2486062-A2 A PROCESS OF MANUFACTURING LOW-FIBRILLATING CELLULOSIC FIBERS Grasim Industries Limited (IN) 2012-08-15 EP claimed
US-8163215-B2 Contains 1-ethyl-3-methylimidazolium acetate; precipitation; spun fibers BASF AKTIENGESELLSCHAFT (DE) 2012-04-24 US claimed
WO-2011048608-A2 A PROCESS OF MANUFACTURING LOW-FIBRILLATING CELLULOSIC FIBERS GRASIM INDUSTRIES LIMITED (IN) 2011-04-28 WO claimed
US-20100256352-A1 METHOD FOR PRODUCING REGENERATED BIOPOLYMERS AND REGENERATED PRODUCTS OBTAINED BY SAID METHOD BASF SE (DE) 2010-10-07 US claimed
US-20080269477-A1 Solvent System Based on Molten Ionic Liquids, Its Production and Use for Producing Regenerated Carbohydrates BASF SE (DE) 2008-10-30 US claimed
EP-4093998-B1 VALVE AUROTEC GMBH (AT) 2025-09-03 EP disclosed
EP-3901333-B1 PRODUCTION OF FILAMENTS WITH CONTROLLED GAS FLOW AUROTEC GMBH (AT) 2025-08-13 EP disclosed
US-12247321-B2 Process for the preparation of polymer fibers from polymers dissolved in ionic liquids by means of an air gap spinning process TECHNIKUM LAUBHOLZ GMBH (DE) 2025-03-11 US disclosed
WO-2011048608-A2 A PROCESS OF MANUFACTURING LOW-FIBRILLATING CELLULOSIC FIBERS GRASIM INDUSTRIES LIMITED (IN) 2011-04-28 WO disclosed
US-20100256352-A1 METHOD FOR PRODUCING REGENERATED BIOPOLYMERS AND REGENERATED PRODUCTS OBTAINED BY SAID METHOD BASF SE (DE) 2010-10-07 US disclosed
US-20100081798-A1 METHOD FOR PRODUCING GLUCOSE BY ENZYMATIC HYDROLYSIS OF CELLULOSE THAT IS OBTAINED FROM MATERIAL CONTAINING LIGNO-CELLULOSE USING AN IONIC LIQUID THAT COMPRISES A POLYATOMIC ANION BASF SE (DE) 2010-04-01 US disclosed
US-20080269477-A1 Solvent System Based on Molten Ionic Liquids, Its Production and Use for Producing Regenerated Carbohydrates BASF SE (DE) 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081798-A1 METHOD FOR PRODUCING GLUCOSE BY ENZYMATIC HYDROLYSIS OF CELLULOSE THAT IS OBTAINED FROM MATERIAL CONTAINING LIGNO-CELLULOSE USING AN IONIC LIQUID THAT COMPRISES A POLYATOMIC ANION MGAM, LCT, SI FABP3 2942/4885MEN1 2926/4885HSP90AA1 4744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.